US2023364178A1PendingUtilityA1
Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells
Assignee: UNIV NEW YORK STATE RES FOUNDPriority: Nov 26, 2007Filed: Sep 27, 2022Published: Nov 16, 2023
Est. expiryNov 26, 2027(~1.3 yrs left)· nominal 20-yr term from priority
A61K 38/03A61K 31/155A61K 31/4995A61K 38/10A61K 38/1709A61K 38/1758C07K 14/4746A61K 47/54A61K 45/06C07K 2319/03A61P 35/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating cancer in a subject, said method comprising:
providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including:
an HDM-2 binding component selected from the group consisting of:
12-26 p53 protein, residues
(SEQ ID NO: 1)
(PPLSQETFSDLWKLL),
17-26 p53 protein, residues
(SEQ ID NO: 2)
(ETFSDLWKLL),
12-26 p53 protein, residues
(SEQ ID NO: 1)
(P*P*LSQETFSDLWKLL),
17-26 p53 protein, residues
(SEQ ID NO: 2)
(E*T*FSDLWKLL),
12-26 p53 protein, residues
(SEQ ID NO: 1)
(P*P*L*SQETFSDLWKLL),
and
(SEQ ID NO. 10)
XFMXXXEXLX,
where X in first position is actyl moiety (CHO), X in fourth position is alpha-amino-isobutyric acid, X in fifth position is phosphonomethyl-phenylalanine, X in sixth position is 6-chlorotryptophan, X in eighth position is 1-amino-cyclopropanecarboxylic acid, X in tenth position is NH2; and
a membrane resident component selected from the group consisting of:
(SEQ ID NO: 3)
KKWKMRRNQFWVKVQRG,
and
(SEQ ID NO: 12)
KKWKMRRNQFWVKVQRGLLR,
said membrane resident component bound to said HDM-2 binding component;
wherein * denotes D-amino acid, and
wherein selectively necrosing said cancer cell, but does not affect the normal non-cancerous cells.
2 . A method of treating cancer in a subject, said method comprising:
providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including:
an HDM-2 binding component selected from the group consisting of:
12-26 p53 protein, residues
(SEQ ID NO: 1)
(PPLSQETFSDLWKLL),
17-26 p53 protein, residues
(SEQ ID NO: 2)
(ETFSDLWKLL),
12-26 p53 protein, residues
(SEQ ID NO: 1)
(P*P*LSQETFSDLWKLL),
17-26 p53 protein, residues
(SEQ ID NO: 2)
(E*T*FSDLWKLL),
12-26 p53 protein, residues
(SEQ ID NO: 1)
(P*P*L*SQETFSDLWKLL),
XFMXXXEXLX,
where X in first position is actyl moiety (CHO), X in fourth position is alpha-amino-isobutyric acid, X in fifth position is phosphonomethyl-phenylalanine, X in sixth position is 6-chlorotryptophan, X in eighth position is 1-amino-cyclopropanecarboxylic acid, X in tenth position is NH2 (SEQ ID NO. 10; and
a membrane resident component selected from the group consisting of:
(SEQ ID NO: 3)
K*K*WKMRRNQFWVKVQRG,
(SEQ ID NO: 11)
K*K*WKMRRNQFWVKVQRGLLR
wherein X is actyl moiety (CHO), and
said membrane resident component bound to said HDM-2 binding component;
wherein * denotes D-amino acid, and
wherein selectively necrosing said cancer cell, but does not affect the normal non-cancerous cells.
3 . The method of claim 1 , further comprising the step of observing in a medium of the cancer cells an early release of LDH.
4 . The method of claim 1 , further comprising the step of observing membranolysis of said cancer cells.
5 . The method of claim 1 , further comprising the step of observing a decrease from a number of pretreatment cancer cells to a number of post treatment cancer cells.
6 . The method of claim 1 , further comprising the step of repeating the administering step until a result is reached.
7 . The method of claim 1 , further comprising the step of observing necrosis in the cancer cells.
8 . The method of claim 1 , further comprising the step of observing a non-response in the normal cell, wherein the non-response indicates the normal cell is unaffected.
9 . The method of claim 1 , wherein the administering step further comprises administering a PNC-27 (SEQ ID NO: 5) peptide, a PNC-28 (SEQ ID NO: 6) peptide, or combinations thereof.
10 . The method of claim 1 , wherein the HDM-2 binding component is 12-26 p53 protein, residues
(SEQ ID NO: 1)
(PPLSQETFSDLWKLL),
11 . The method of claim 1 , wherein the HDM-2 binding component is 17-26 p53 protein, residues
(SEQ ID NO: 2)
(ETFSDLWKLL),
12 . The method of claim 1 , wherein the membrane resident component is
(SEQ ID NO: 3)
KKWKMRRNQFWVKVQRG
13 . The method of claim 10 , wherein the membrane resident component is
(SEQ ID NO: 3)
KKWKMRRNQFWVKVQRG
14 . The method of claim 11 , wherein the membrane resident component is
(SEQ ID NO: 3)
KKWKMRRNQFWVKVQRG
15 . The method of claim 2 , wherein the HDM-2 binding component is 12-26 p53 protein, residues
(SEQ ID NO: 1)
(PPLSQETFSDLWKLL)
16 . The method of claim 2 , wherein the HDM-2 binding component is 17-26 p53 protein, residues
(SEQ ID NO: 2)
ETFSDLWKLL)
17 . The method of claim 2 , wherein the membrane resident component is
(SEQ ID NO: 3)
KKWKMRRNQFWVKVQRG
18 . The method of claim 15 , wherein the membrane resident component is
(SEQ ID NO: 3)
KKWKMRRNQFWVKVQRG
19 . The method of claim 16 , wherein the membrane resident component is
(SEQ ID NO: 3)
KKWKMRRNQFWVKVQRG
20 . The method of claim 1 , wherein selective necrosis comprises pore formation.Join the waitlist — get patent alerts
Track US2023364178A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.